Investigation into Option Care Health Investor Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy OPCH?
Source: Globenewswire
- Declining Financial Performance: Option Care Health reported Q1 2026 net revenue of $1.35 billion, reflecting only a 1.3% year-over-year growth, while adjusted EBITDA fell by 6.3%, indicating a significant decline in profitability that could undermine investor confidence.
- Guidance Downgrade: The company lowered its full-year 2026 net revenue guidance to a range of $5.675 billion to $5.775 billion, down from the previous $5.8 billion to $6.0 billion, reflecting a pessimistic outlook on future performance that may lead to further stock price declines.
- Chronic Business Growth Slowdown: The report indicated a decline in revenue growth from the chronic business, with the chronic inflammatory disease portfolio expected to create an approximately 600 basis point headwind to total company net revenue growth in 2026, exacerbating investor concerns.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Option Care Health complied with federal securities laws, and investors who suffered losses from holding the company's stock may have the opportunity to seek compensation through legal channels, highlighting concerns over corporate governance and compliance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OPCH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OPCH
Wall Street analysts forecast OPCH stock price to rise
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 26.870
Low
27.00
Averages
36.22
High
40.00
Current: 26.870
Low
27.00
Averages
36.22
High
40.00
About OPCH
Option Care Health, Inc. is an independent provider of home and alternate site infusion services. The Company’s infusion services include the clinical management of infusion therapy, nursing support and care coordination. It provides a therapy portfolio through its network of 92 full-service pharmacies and 93 stand-alone ambulatory infusion suites. It administers a wide variety of therapies and services, including anti-infectives infusion, nutrition support, immunoglobulin infusion, chronic inflammatory disorders, neurological disorders, bleeding disorders infusion, Naven health, women’s health, heart failure, and others. Its home infusion services include medication and supplies for administration and use at home or within one of its ambulatory infusion suites, consultation and education regarding the patient’s condition and the prescribed medication nursing support, clinical monitoring and assistance in monitoring potential side effects, and assistance in obtaining reimbursement.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Block & Leviton Investigates Option Care Health for Securities Violations
- Stock Price Plunge: Option Care Health, Inc. saw its stock drop over 30% on April 30, 2026, following the release of its first-quarter results and a cut in its full-year revenue guidance, primarily due to an unexpected reset in patient census in its chronic inflammatory disease portfolio, including conversions of the Stelara biosimilar.
- Revenue Guidance Cut: Earlier in 2026, the company had maintained its full-year revenue guidance and stated that its related patient census assumptions were aligned with expectations, but this adjustment indicates a significant shift in market demand, potentially undermining investor confidence.
- Legal Investigation Launched: Block & Leviton is investigating whether Option Care Health committed securities law violations and may file actions to recover losses on behalf of investors, indicating that the company faces legal risks that could impact its future financial performance.
- Investor Action Recommendation: Affected investors are encouraged to contact Block & Leviton to learn how to recover their losses, demonstrating the firm's proactive stance in protecting investor rights while potentially attracting more investor attention to the company's legal compliance.
See More
Investigation into Option Care Health Investor Claims
- Declining Financial Performance: Option Care Health reported Q1 2026 net revenue of $1.35 billion, reflecting only a 1.3% year-over-year growth, while adjusted EBITDA fell by 6.3%, indicating a significant decline in profitability that could undermine investor confidence.
- Guidance Downgrade: The company lowered its full-year 2026 net revenue guidance to a range of $5.675 billion to $5.775 billion, down from the previous $5.8 billion to $6.0 billion, reflecting a pessimistic outlook on future performance that may lead to further stock price declines.
- Chronic Business Growth Slowdown: The report indicated a decline in revenue growth from the chronic business, with the chronic inflammatory disease portfolio expected to create an approximately 600 basis point headwind to total company net revenue growth in 2026, exacerbating investor concerns.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Option Care Health complied with federal securities laws, and investors who suffered losses from holding the company's stock may have the opportunity to seek compensation through legal channels, highlighting concerns over corporate governance and compliance.
See More
Option Care Health Q1 Revenue Misses Expectations, Lowers Full-Year Outlook
- Revenue Performance Miss: Option Care Health reported $1.4 billion in Q1 2026 revenue with approximately 2% YoY growth, falling short of Street forecasts by $50 million, indicating a lack of growth momentum that could undermine investor confidence moving forward.
- Adjusted EPS Beats Expectations: Despite the revenue miss, the company’s adjusted EPS of $0.40 exceeded consensus by $0.03, demonstrating effective cost management that may alleviate some investor concerns amidst the disappointing revenue figures.
- Full-Year Revenue Outlook Cut: The company lowered its full-year revenue guidance to $5.675 billion - $5.775 billion, down from the previous $5.8 billion - $6.0 billion forecast, which could lead to diminished market confidence in the company’s growth potential.
- Operating Margin Decline: The operating margin for Q1 stood at 5.4%, down from 5.9% in the prior year, indicating challenges in cost management and operational efficiency that may impact long-term profitability and competitive positioning.
See More
Option Care Health to Announce Q1 Earnings on April 30
- Earnings Announcement: Option Care Health (OPCH) is set to announce its Q1 2023 earnings on April 30 before market open, with consensus EPS estimate at $0.37, reflecting a 7.5% year-over-year decline, while revenue is projected at $1.4 billion, indicating a 5.3% increase year-over-year.
- Performance Expectations: Over the past year, OPCH has exceeded EPS estimates 75% of the time and has beaten revenue estimates 100% of the time, showcasing the company's consistent profitability and market confidence.
- Revision Trends: In the last three months, EPS estimates have seen one upward revision and seven downward revisions, while revenue estimates have experienced no upward revisions and eight downward revisions, indicating a cautious market outlook on the company's future performance.
- Future Guidance: Option Care Health outlines a revenue guidance of $5.8 billion to $6 billion for 2026, while expanding its infusion clinic network to support future growth potential.
See More
U.S. Healthcare Stocks Plunge Amid Geopolitical Tensions
- Oversold Healthcare Stocks: The ongoing geopolitical tensions have led to significant selling pressure in healthcare stocks, with Merit Medical Systems (MMSI) and Option Care Health (OPCH) showing RSIs of 29.03 and 28.79 respectively, indicating strong sell sentiment in the market.
- Potential for Short-term Rebound: While the current oversold conditions typically signal heavy selling, these healthcare stocks could be well-positioned for a quick bounce-back if geopolitical news improves, particularly for companies like Crinetics Pharmaceuticals (CRNX) and Prestige Consumer Healthcare (PBH).
- Increased Market Volatility: As the conflict enters its 16th day, overall market volatility has intensified, pushing several key sectors into technically oversold territory, with 15-day performance showing widespread declines, including Bio-Techne Corporation (TECH) down 13.81% and iRhythm Holdings (IRTC) down 15.51%.
- Investor Focus: Amid the turmoil in the Middle East, investor attention on healthcare stocks has risen, especially for companies like Eli Lilly and Novo Nordisk, with the market eagerly anticipating their future performance amidst the current challenges.
See More
US Stocks Rebound Led by Software and Chipmakers
- Market Rebound: The S&P 500 Index rose by 0.77%, the Dow Jones Industrial Average increased by 0.76%, and the Nasdaq 100 Index climbed by 1.09%, indicating a recovery after Monday's sharp declines, reflecting investor optimism regarding economic data.
- Software and Chip Stocks Surge: Following AI startup Anthropic PBC's emphasis on partnerships, software and chip manufacturers saw significant stock price increases, indicating growing market confidence in the integration of AI technologies, which could enhance their competitive positioning.
- Consumer Confidence Boost: The US February consumer confidence index rose by 2.2 to 91.2, surpassing expectations of 87.1, suggesting increased consumer optimism about the economic outlook, which may lead to higher consumer spending and positively impact economic growth.
- Interest Rates and Economic Data Focus: The market is discounting only a 2% chance of a rate cut at the Fed's March 17-18 meeting, indicating cautious investor sentiment regarding future monetary policy, while closely monitoring upcoming corporate earnings and economic data releases.
See More
Block & Leviton Investigates Option Care Health for Securities Violations
- Stock Price Plunge: Option Care Health, Inc. saw its stock drop over 30% on April 30, 2026, following the release of its first-quarter results and a cut in its full-year revenue guidance, primarily due to an unexpected reset in patient census in its chronic inflammatory disease portfolio, including conversions of the Stelara biosimilar.
- Revenue Guidance Cut: Earlier in 2026, the company had maintained its full-year revenue guidance and stated that its related patient census assumptions were aligned with expectations, but this adjustment indicates a significant shift in market demand, potentially undermining investor confidence.
- Legal Investigation Launched: Block & Leviton is investigating whether Option Care Health committed securities law violations and may file actions to recover losses on behalf of investors, indicating that the company faces legal risks that could impact its future financial performance.
- Investor Action Recommendation: Affected investors are encouraged to contact Block & Leviton to learn how to recover their losses, demonstrating the firm's proactive stance in protecting investor rights while potentially attracting more investor attention to the company's legal compliance.
See More
Investigation into Option Care Health Investor Claims
- Declining Financial Performance: Option Care Health reported Q1 2026 net revenue of $1.35 billion, reflecting only a 1.3% year-over-year growth, while adjusted EBITDA fell by 6.3%, indicating a significant decline in profitability that could undermine investor confidence.
- Guidance Downgrade: The company lowered its full-year 2026 net revenue guidance to a range of $5.675 billion to $5.775 billion, down from the previous $5.8 billion to $6.0 billion, reflecting a pessimistic outlook on future performance that may lead to further stock price declines.
- Chronic Business Growth Slowdown: The report indicated a decline in revenue growth from the chronic business, with the chronic inflammatory disease portfolio expected to create an approximately 600 basis point headwind to total company net revenue growth in 2026, exacerbating investor concerns.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Option Care Health complied with federal securities laws, and investors who suffered losses from holding the company's stock may have the opportunity to seek compensation through legal channels, highlighting concerns over corporate governance and compliance.
See More
Option Care Health Q1 Revenue Misses Expectations, Lowers Full-Year Outlook
- Revenue Performance Miss: Option Care Health reported $1.4 billion in Q1 2026 revenue with approximately 2% YoY growth, falling short of Street forecasts by $50 million, indicating a lack of growth momentum that could undermine investor confidence moving forward.
- Adjusted EPS Beats Expectations: Despite the revenue miss, the company’s adjusted EPS of $0.40 exceeded consensus by $0.03, demonstrating effective cost management that may alleviate some investor concerns amidst the disappointing revenue figures.
- Full-Year Revenue Outlook Cut: The company lowered its full-year revenue guidance to $5.675 billion - $5.775 billion, down from the previous $5.8 billion - $6.0 billion forecast, which could lead to diminished market confidence in the company’s growth potential.
- Operating Margin Decline: The operating margin for Q1 stood at 5.4%, down from 5.9% in the prior year, indicating challenges in cost management and operational efficiency that may impact long-term profitability and competitive positioning.
See More
Option Care Health to Announce Q1 Earnings on April 30
- Earnings Announcement: Option Care Health (OPCH) is set to announce its Q1 2023 earnings on April 30 before market open, with consensus EPS estimate at $0.37, reflecting a 7.5% year-over-year decline, while revenue is projected at $1.4 billion, indicating a 5.3% increase year-over-year.
- Performance Expectations: Over the past year, OPCH has exceeded EPS estimates 75% of the time and has beaten revenue estimates 100% of the time, showcasing the company's consistent profitability and market confidence.
- Revision Trends: In the last three months, EPS estimates have seen one upward revision and seven downward revisions, while revenue estimates have experienced no upward revisions and eight downward revisions, indicating a cautious market outlook on the company's future performance.
- Future Guidance: Option Care Health outlines a revenue guidance of $5.8 billion to $6 billion for 2026, while expanding its infusion clinic network to support future growth potential.
See More
U.S. Healthcare Stocks Plunge Amid Geopolitical Tensions
- Oversold Healthcare Stocks: The ongoing geopolitical tensions have led to significant selling pressure in healthcare stocks, with Merit Medical Systems (MMSI) and Option Care Health (OPCH) showing RSIs of 29.03 and 28.79 respectively, indicating strong sell sentiment in the market.
- Potential for Short-term Rebound: While the current oversold conditions typically signal heavy selling, these healthcare stocks could be well-positioned for a quick bounce-back if geopolitical news improves, particularly for companies like Crinetics Pharmaceuticals (CRNX) and Prestige Consumer Healthcare (PBH).
- Increased Market Volatility: As the conflict enters its 16th day, overall market volatility has intensified, pushing several key sectors into technically oversold territory, with 15-day performance showing widespread declines, including Bio-Techne Corporation (TECH) down 13.81% and iRhythm Holdings (IRTC) down 15.51%.
- Investor Focus: Amid the turmoil in the Middle East, investor attention on healthcare stocks has risen, especially for companies like Eli Lilly and Novo Nordisk, with the market eagerly anticipating their future performance amidst the current challenges.
See More
US Stocks Rebound Led by Software and Chipmakers
- Market Rebound: The S&P 500 Index rose by 0.77%, the Dow Jones Industrial Average increased by 0.76%, and the Nasdaq 100 Index climbed by 1.09%, indicating a recovery after Monday's sharp declines, reflecting investor optimism regarding economic data.
- Software and Chip Stocks Surge: Following AI startup Anthropic PBC's emphasis on partnerships, software and chip manufacturers saw significant stock price increases, indicating growing market confidence in the integration of AI technologies, which could enhance their competitive positioning.
- Consumer Confidence Boost: The US February consumer confidence index rose by 2.2 to 91.2, surpassing expectations of 87.1, suggesting increased consumer optimism about the economic outlook, which may lead to higher consumer spending and positively impact economic growth.
- Interest Rates and Economic Data Focus: The market is discounting only a 2% chance of a rate cut at the Fed's March 17-18 meeting, indicating cautious investor sentiment regarding future monetary policy, while closely monitoring upcoming corporate earnings and economic data releases.
See More
